Showing results (1-10 of 60) with videos related to

Sort By:
Pageof 6
Anti-Cancer Drugs|August 4, 2010
Monitoring long-term treatment with pegylated liposomal doxorubicin: how important is intensive cardiac follow-up?Tal Grenader, Anthony Goldberg, Alberto Gabizon
European Journal of Pharmaceutical Sciences : Official Journal of the European Federation for Pharmaceutical Sciences|September 22, 2011
Pharmacological basis of pegylated liposomal doxorubicin: impact on cancer therapyAlberto Gabizon, Hilary Shmeeda, Tal Grenader
Clinical Pharmacokinetics|May 13, 2003
Pharmacokinetics of pegylated liposomal Doxorubicin: review of animal and human studiesAlberto Gabizon, Hilary Shmeeda, Yechezkel Barenholz
Lung Cancer (Amsterdam, Netherlands)|March 27, 2007
Significant drug interaction: phenytoin toxicity due to erlotinibTal Grenader, Maya Gipps, Linda Shavit, et al.
Advanced Drug Delivery Reviews|July 27, 2011
Activation of complement by therapeutic liposomes and other lipid excipient-based therapeutic products: prediction and preventionJanos Szebeni, Franco Muggia, Alberto Gabizon, et al.
Journal of Controlled Release : Official Journal of the Controlled Release Society|April 1, 2009
Her2-targeted pegylated liposomal doxorubicin: retention of target-specific binding and cytotoxicity after in vivo passageHilary Shmeeda, Dina Tzemach, Lidia Mak, et al.
ACS Nano|June 27, 2019
Integrating Nanotechnology into Cancer CarePiotr Grodzinski, Moritz Kircher, Michael Goldberg, et al.
Advanced Drug Delivery Reviews|April 20, 2004
Tumor cell targeting of liposome-entrapped drugs with phospholipid-anchored folic acid-PEG conjugatesAlberto Gabizon, Hilary Shmeeda, Aviva T Horowitz, et al.
Pageof 6